{"id":"NCT01988012","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis.","officialTitle":"An Open-label, Multicenter Study to Evaluate Disease Activity and Safety of Treatment With Actemra (Tocilizumab) Administered as Subcutaneous Injection in Adult RA Patients.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01","primaryCompletion":"2015-07","completion":"2015-07","firstPosted":"2013-11-20","resultsPosted":"2017-03-06","lastUpdate":"2017-03-06"},"enrollment":100,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"BIOLOGICAL","name":"tocilizumab","otherNames":["RoActemra/Actemra"]}],"arms":[{"label":"Tocilizumab","type":"EXPERIMENTAL"}],"summary":"A multi-center, open-label single-arm study to evaluate the efficacy and safety of tocilizumab administered as a single, weekly injection in adults with rheumatoid arthritis. Combination therapy with methotrexate or other non-biologic disease modifying anti-rheumatic drugs (DMARDs) was permitted.","primaryOutcome":{"measure":"Percentage of Participants With Clinical Disease Activity Index (CDAI) Remission and CDAI Low Disease Activity","timeFrame":"Week 24","effectByArm":[{"arm":"Tocilizumab","deltaMin":16.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":19},"locations":{"siteCount":13,"countries":["Israel"]},"refs":{"pmids":["30649524","29244149"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":100},"commonTop":["Neutropenia","Leukopenia","Hepatic enzyme increased","Alanine aminotransferase increased","Upper respiratory tract infection"]}}